A 58-year-old man from Delhi presents with progressive dyspnea on exertion for 3 months, orthopnea, and paroxysmal nocturnal dyspnea. He has a history of hypertension (BP 165/95 mmHg) and type 2 diabetes. On examination, he has bilateral crackles at lung bases, elevated JVP, and a displaced apical impulse. Echocardiography shows LVEF 35%, global hypokinesis, and no significant valvular disease. Serum creatinine is 1.4 mg/dL, K⁺ 4.2 mEq/L, and BNP 850 pg/mL. He is started on lisinopril and furosemide. Which of the following should be added NEXT to reduce mortality in this patient?

Explanation

## Clinical Diagnosis This patient has **systolic heart failure (HFrEF)** with LVEF 35%, secondary to hypertension and diabetes. He is already on an ACE inhibitor (lisinopril) and a diuretic. ## Mortality-Reducing Therapy in HFrEF **Key Point:** The cornerstone medications proven to reduce mortality in HFrEF are: 1. ACE inhibitors / ARBs (already started) 2. **Beta-blockers** (next essential agent) 3. Aldosterone antagonists (if indicated) 4. SGLT2 inhibitors (newer evidence) ## Why Carvedilol? **High-Yield:** Beta-blocers (carvedilol, metoprolol succinate, bisoprolol) are Class I evidence for mortality reduction in HFrEF. They reduce sympathetic overactivity, improve LV remodeling, and prevent sudden cardiac death. Carvedilol has additional alpha-blocking properties and is preferred in hypertensive HFrEF. **Clinical Pearl:** The sequence of HFrEF therapy is: ACE-I/ARB → Beta-blocker → Aldosterone antagonist → SGLT2 inhibitor. Each agent is added sequentially once the previous one is tolerated and optimized. ## Why Not the Others? | Agent | Reason | |-------|--------| | **Amlodipine** | Calcium channel blocker; no mortality benefit in HFrEF. Can worsen heart failure if used as monotherapy. | | **Hydralazine + ISDN** | Reserved for HFrEF in African Americans (INHEST trial) or those intolerant to ACE-I/ARB/beta-blockers. Not first-line after ACE-I. | | **Spironolactone alone** | Aldosterone antagonist is added AFTER beta-blocker optimization, not before. Also requires monitoring of K⁺ and creatinine. | ## Treatment Algorithm ```mermaid flowchart TD A[HFrEF diagnosed]:::outcome --> B[Start ACE-I/ARB + Diuretic]:::action B --> C{Tolerated?}:::decision C -->|Yes| D[Add Beta-blocker]:::action D --> E{Tolerated & optimized?}:::decision E -->|Yes| F[Add Aldosterone antagonist]:::action E -->|No| G[Uptitrate beta-blocker]:::action F --> H[Consider SGLT2 inhibitor]:::action C -->|No| I[Adjust dose/agent]:::action ``` [cite:Harrison 21e Ch 297]